Mobilization of bone marrow-derived mesenchymal stem cells in the treatment of ischemic cardiomyopathy
- VernacularTitle:骨髓间充质干细胞动员及在缺血性心肌疾病治疗中的应用
- Author:
Guiping YU
- Publication Type:Journal Article
- From:
Chinese Journal of Tissue Engineering Research
2008;12(25):4983-4986
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND: Mobilization of autologous bone marrow-derived mesenchymal stem cells (MSCs) for repair of myocardialnecrosis is a safe and effective method for treatment of ischemic cardiomyopathy. OBJECTIVE: This review serves to summarize the research progress in mobilization of bone marrow-derived MSCs for treatment of ischemic cardiomyopathy. RETRIEVAL STRATEGY: Using the terms "bone marrow stem cells, myocardial infarction", manuscripts that were published from December 1996 to December 2006 were retrieved from the PubMed database. Manuscripts were primarily screened. Inclusion criteria: studies on bone marrow-derived MSCs used for treatment of ischemic cardiomyopathy, and studies that were recently published or in high-impact journals. Exclusion criteria: repetitive studies. LITERATURE EVALUATION: The manuscripts primarily focused on the randomized controlled experiments of bone marrow-derived MSCs for treatment of ischemic cardiomyopathy. Among the 28 included manuscripts, 28 were review studies, and the remaining were clinical or basic experimental studies. DATA SYNTHESIS: Bone marrow-derived MSCs possess self-renewal, proliferative, and multi-directional differentiation potential. They can differentiate into cardiac-like cells under the regulation of appropriate cytokines. Previous studies have demonstrated that the stem cells in the bone marrow blood circulation can reach infarcted myocardium and are involved in the tissue regeneration. A great progress has been made in the study on bone marrow-derived MSCs used for treatment of ischemic cardiomyopathy. However, there exist some problems, such as, how to preserve the seeded cells, the mechanism underlying differentiation and proliferation in the in vitro culture of cells remains unclear, and the biomechanical performance of cardiac-like cells are not satisfactory. CONCLUSION: Mobilization of bone marrow-derived MSCs is easy, fast, less-injury, and without immunologic rejections in the autotransplantation for treatment of isehemic cardiomyopathy. However, there are still some unsolved problems.
